1
|
Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye. Eur J Clin Microbiol Infect Dis 2024:10.1007/s10096-024-04896-7. [PMID: 38995343 DOI: 10.1007/s10096-024-04896-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Accepted: 07/02/2024] [Indexed: 07/13/2024]
Abstract
PURPOSE Carbapenem resistant Pseudomonas aeruginosa (CR-PA) is escalating worldwide and leaves clinicians few therapeutic options in recent years, β-lactam/β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam) and a new siderophore cephalosporin (cefiderocol) have been approved for the treatment of P. aeruginosa infection and have shown potent activity against isolates defined as carbapenem resistant. The aim of this study was to determine the phenotypic profile of these agents against CR-PA in the emerging setting of carbapenemases. METHODS CR-PA clinical isolates were collected from three teaching hospitals in different geographical regions between January 2017-December 2021. All isolates were subjected to phenotypic carbapenemase testing using modified carbapenem inactivation method. MICs were determined by reference broth microdilution and evaluated according to EUCAST standards, while genotypic profiling was determined using PCR methods. RESULTS 244 CR-PA sourced most frequently from the respiratory tract (32.2%), blood (20.4%) and urine (17.5%) were evaluated. Of all isolates, 32 (13.1%) were phenotypically and 38 (15.6%) were genotypically defined as carbapenemase-positive. The most common carbapenemase was GES (63.1%), followed by VIM (15.8%). The MIC50/90(S%) of ceftazidime/avibactam, ceftolozane/tazobactam and cefiderocol in all CR-PA isolates were 4 and 32 (80%), 1 and > 64 (69%) and 0.25 and 1 mg/L (96%), respectively. Cefiderocol was also the most active agent in carbapenemase-positive isolates (90%). CONSLUSION While ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against CR-PA devoid of carbapenemases, cefiderocol provided potent in vitro activity irrespective of carbapenemase production. When considering the potential clinical utility of newer agents against CR-PA, regional variations in carbapenemase prevalence must be considered.
Collapse
Affiliation(s)
- Ecem Buyukyanbolu
- Department of Medical Microbiology, Health Sciences University Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
- Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, 06102, CT, USA.
| | - Leyla Genc
- Department of Medical Microbiology, Health Sciences University Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
| | - Elizabeth A Cyr
- Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, 06102, CT, USA
| | - Mehmet Karakus
- Department of Medical Microbiology, Health Sciences University, Istanbul, Turkey
| | - Fusun Comert
- Department of Medical Microbiology, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey
| | - Baris Otlu
- Department of Medical Microbiology, Faculty of Medicine, Inonu University, Malatya, Turkey
| | - Elif Aktas
- Department of Medical Microbiology, Health Sciences University Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
| | - David P Nicolau
- Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, 06102, CT, USA
| |
Collapse
|
2
|
Gondal AJ, Choudhry N, Niaz A, Yasmin N. Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-Resistant Pseudomonas aeruginosa Clinical Strains: A Challenge for Tertiary Care Hospitals. Antibiotics (Basel) 2024; 13:191. [PMID: 38391577 PMCID: PMC10886086 DOI: 10.3390/antibiotics13020191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Revised: 01/09/2024] [Accepted: 01/23/2024] [Indexed: 02/24/2024] Open
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (P. aeruginosa) strains have become a global threat due to their remarkable capability to survive and disseminate successfully by the acquisition of resistance genes. As a result, the treatment strategies have been severely compromised. Due to the insufficient available data regarding P. aeruginosa resistance from Pakistan, we aimed to investigate the resistance mechanisms of 249 P. aeruginosa strains by antimicrobial susceptibility testing, polymerase chain reaction for the detection of carbapenemases, aminoglycoside resistance genes, extended-spectrum beta-lactamases (ESBLs), sequence typing and plasmid typing. Furthermore, we tested silver nanoparticles (AgNPs) to evaluate their in vitro sensitivity against antimicrobial-resistant P. aeruginosa strains. We observed higher resistance against antimicrobials in the general surgery ward, general medicine ward and wound samples. Phenotypic carbapenemase-producer strains comprised 80.7% (201/249) with 89.0% (179/201) demonstrating genes encoding carbapenemases: blaNDM-1 (32.96%), blaOXA48 (37.43%), blaIMP (7.26%), blaVIM (5.03%), blaKPC-2 (1.12%), blaNDM-1/blaOXA48 (13.97%), blaOXA-48/blaVIM (1.68%) and blaVIM/blaIMP (0.56%). Aminoglycoside-modifying enzyme genes and 16S rRNA methylase variants were detected in 43.8% (109/249) strains: aac(6')-lb (12.8%), aac(3)-lla (12.0%), rmtB (21.1%), rmtC (11.0%), armA (12.8%), rmtD (4.6%), rmtF (6.4%), rmtB/aac(3)-lla (8.2%), rmtB/aac(6')-lla (7.3%) and rmtB/armA (3.6%). In total, 43.0% (77/179) of the strains coharbored carbapenemases and aminoglycoside resistance genes with 83.1% resistant to at least 1 agent in 3 or more classes and 16.9% resistant to every class of antimicrobials tested. Thirteen sequence types (STs) were identified: ST235, ST277, ST234, ST170, ST381, ST175, ST1455, ST1963, ST313, ST207, ST664, ST357 and ST348. Plasmid replicon types IncFI, IncFII, IncA/C, IncL/M, IncN, IncX, IncR and IncFIIK and MOB types F11, F12, H121, P131 and P3 were detected. Meropenem/AgNPs and Amikacin/AgNPs showed enhanced antibacterial activity. We reported the coexistence of carbapenemases and aminoglycoside resistance genes among carbapenem-resistant P. aeruginosa with diverse clonal lineages from Pakistan. Furthermore, we highlighted AgNP's potential role in handling future antimicrobial resistance concerns.
Collapse
Affiliation(s)
- Aamir Jamal Gondal
- Department of Biomedical Sciences, King Edward Medical University, Lahore 54000, Pakistan
| | - Nakhshab Choudhry
- Department of Biochemistry, King Edward Medical University, Lahore 54000, Pakistan
| | - Ammara Niaz
- Department of Biochemistry, King Edward Medical University, Lahore 54000, Pakistan
| | - Nighat Yasmin
- Department of Biomedical Sciences, King Edward Medical University, Lahore 54000, Pakistan
| |
Collapse
|
3
|
Martínez-Zavaleta MG, Fernández-Rodríguez D, Hernández-Durán M, Colín-Castro CA, de Lourdes García-Hernández M, Becerra-Lobato N, Franco-Cendejas R, López-Jácome LE. Acquired blaVIM and blaGES Carbapenemase-Encoding Genes in Pseudomonas aeruginosa: A Seven-Year Survey Highlighting an Increasing Epidemiological Threat. Pathogens 2023; 12:1256. [PMID: 37887772 PMCID: PMC10610504 DOI: 10.3390/pathogens12101256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 10/10/2023] [Accepted: 10/16/2023] [Indexed: 10/28/2023] Open
Abstract
(1) Background: Pseudomonas aeruginosa is a Gram-negative bacterium with several intrinsic and acquired antimicrobial resistance mechanisms. The spread of carbapenemase-encoding genes, an acquired mechanism, enables carbapenem resistance in clinical settings. Detection of the carbapenemase-producer strains is urgent. Therefore, we aimed to characterize carbapenemase production in the clinical strains of P. aeruginosa at a tertiary-care center. (2) Methods: We included clinical strains of P. aeruginosa (from August 2011 to December 2018) with resistance towards at least one carbapenem. Strains were isolated in a tertiary-care center in Mexico City. Antimicrobial susceptibility profiles were determined by broth microdilution. Screening for carbapenemase-encoding genes was performed in all strains. Phenotypic assays (CarbaNP and mCIM) were conducted. Additional modifications to mCIM were also tested. (3) Results: One-hundred seventy-one P. aeruginosa strains out of 192 included in this study were resistant towards at least one of the carbapenems tested. Forty-seven of these strains harbored a carbapenemase-encoding gene. VIM (59.6%) and GES (23.4%) were the most frequently found carbapenemases in our study, followed by IMP (14.9%). (4) Among the most frequent carbapenemase genes identified, metallo-ß-lactamases were the most prevalent, which impair new treatment options. Searching for carbapenemase genes should be performed in resistant isolates to stop transmission and guide antimicrobial treatment.
Collapse
Affiliation(s)
- María Guadalupe Martínez-Zavaleta
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
| | - Diana Fernández-Rodríguez
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
- Plan de Estudios Combinados en Medicina (PECEM) MD/PhD, Facultad de Medicina, Universidad Nacional Autónoma de México, Circuito Escolar S/N, Ciudad Universitaria, Av. Universidad 3000, Mexico City 04510, Mexico
| | - Melissa Hernández-Durán
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
| | - Claudia A. Colín-Castro
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
| | - María de Lourdes García-Hernández
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
| | - Noé Becerra-Lobato
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
| | - Rafael Franco-Cendejas
- Biomedical Research Subdirection, Research Direction, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico
| | - Luis Esaú López-Jácome
- Clinical Microbiology Laboratory, Infectious Diseases Division, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra, Calz, México-Xochimilco No. 289, Col. Arenal de Guadalupe, Mexico City 14389, Mexico; (M.G.M.-Z.); (D.F.-R.); (M.H.-D.); (C.A.C.-C.); (M.d.L.G.-H.); (N.B.-L.)
- Biology Department, Chemistry Faculty, Universidad Nacional Autónoma de México, Circuito Escolar S/N, Ciudad Universitaria, Av. Universidad 3000, Mexico City 04510, Mexico
| |
Collapse
|
4
|
Peykov S, Strateva T. Whole-Genome Sequencing-Based Resistome Analysis of Nosocomial Multidrug-Resistant Non-Fermenting Gram-Negative Pathogens from the Balkans. Microorganisms 2023; 11:microorganisms11030651. [PMID: 36985224 PMCID: PMC10051916 DOI: 10.3390/microorganisms11030651] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 02/28/2023] [Accepted: 03/01/2023] [Indexed: 03/06/2023] Open
Abstract
Non-fermenting Gram-negative bacilli (NFGNB), such as Pseudomonas aeruginosa and Acinetobacter baumannii, are among the major opportunistic pathogens involved in the global antibiotic resistance epidemic. They are designated as urgent/serious threats by the Centers for Disease Control and Prevention and are part of the World Health Organization’s list of critical priority pathogens. Also, Stenotrophomonas maltophilia is increasingly recognized as an emerging cause for healthcare-associated infections in intensive care units, life-threatening diseases in immunocompromised patients, and severe pulmonary infections in cystic fibrosis and COVID-19 individuals. The last annual report of the ECDC showed drastic differences in the proportions of NFGNB with resistance towards key antibiotics in different European Union/European Economic Area countries. The data for the Balkans are of particular concern, indicating more than 80% and 30% of invasive Acinetobacter spp. and P. aeruginosa isolates, respectively, to be carbapenem-resistant. Moreover, multidrug-resistant and extensively drug-resistant S. maltophilia from the region have been recently reported. The current situation in the Balkans includes a migrant crisis and reshaping of the Schengen Area border. This results in collision of diverse human populations subjected to different protocols for antimicrobial stewardship and infection control. The present review article summarizes the findings of whole-genome sequencing-based resistome analyses of nosocomial multidrug-resistant NFGNBs in the Balkan countries.
Collapse
Affiliation(s)
- Slavil Peykov
- Department of Genetics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, 8, Dragan Tzankov Blvd., 1164 Sofia, Bulgaria
- Department of Medical Microbiology, Faculty of Medicine, Medical University of Sofia, 2, Zdrave Str., 1431 Sofia, Bulgaria
- BioInfoTech Laboratory, Sofia Tech Park, 111, Tsarigradsko Shosse Blvd., 1784 Sofia, Bulgaria
- Correspondence: (S.P.); (T.S.); Tel.: +359-87-6454492 (S.P.); +359-2-9172750 (T.S.)
| | - Tanya Strateva
- Department of Medical Microbiology, Faculty of Medicine, Medical University of Sofia, 2, Zdrave Str., 1431 Sofia, Bulgaria
- Correspondence: (S.P.); (T.S.); Tel.: +359-87-6454492 (S.P.); +359-2-9172750 (T.S.)
| |
Collapse
|
5
|
Jousset AB, Bernabeu S, Emeraud C, Bonnin RA, Lomont A, Zahar JR, Merens A, Isnard C, Soismier N, Farfour E, Fihman V, Yin N, Barraud O, Jacquier H, Ranc AG, Laurent F, Corvec S, d'Epenoux LR, Bille E, Degand N, Plouzeau C, Guillard T, Cattoir V, Mizrahi A, Grillon A, Janvier F, Brun CL, Amara M, Bastide M, Lemonnier A, Dortet L. Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales. J Glob Antimicrob Resist 2023; 32:78-84. [PMID: 36708769 DOI: 10.1016/j.jgar.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 12/22/2022] [Accepted: 01/13/2023] [Indexed: 01/27/2023] Open
Abstract
OBJECTIVES Ceftolozane-tazobactam (C/T) proved its efficacy for the treatment of infections caused by non-carbapenemase producing Pseudomonas aeruginosa and Enterobacterales. Here, we aimed to provide susceptibility data on a large series of Enterobacterales since the revision of EUCAST categorization breakpoints in 2020. METHODS First, C/T susceptibility was determined on characterized Enterobacterales resistant to third generation cephalosporins (3GCs) (extended spectrum β-lactamase [ESBL] production or different levels of AmpC overexpression) (n = 213) and carbapenem-resistant Enterobacterales (CRE) (n = 259), including 170 carbapenemase producers (CPE). Then, 1632 consecutive clinical Enterobacterales responsible for infection were prospectively collected in 23 French hospitals. C/T susceptibility was determined by E-test® (biomérieux) and broth microdilution (BMD) (Sensititre™, Thermo Scientific) to perform method comparison. RESULTS Within the collection isolates, 88% of 3GC resistant strains were susceptible to C/T, with important variation depending on the resistance mechanism: 93% vs. 13% susceptibility for CTX-M and SHV-ESBL producers, respectively. Only 20% of the CRE were susceptible to C/T. Among CPE, 80% of OXA-48-like producers were susceptible to C/T, whereas all metallo-β-lactamase producers were resistant. The prospective study revealed that 95.6% of clinical isolates were susceptible to C/T. Method comparison performed on these 1632 clinical isolates demonstrated 99% of categorization agreement between MIC to C/T determined by E-test® in comparison with the BMD (reference) and only 74% of essential agreement. CONCLUSION Overall, C/T showed good activity against wild-type Enterobacterales, AmpC producers, and ESBL-producing Escherichia coli but is less active against ESBL-producing Klebsiella pneumoniae, and CRE. E-test® led to an underestimation of the MICs in comparison to the BMD reference.
Collapse
Affiliation(s)
- Agnès B Jousset
- INSERM UMR1184 Team 'Resist', Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France
| | - Sandrine Bernabeu
- INSERM UMR1184 Team 'Resist', Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France
| | - Cécile Emeraud
- INSERM UMR1184 Team 'Resist', Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France; CHU de Bicêtre, Service de Bactériologie-Hygiène, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
| | - Rémy A Bonnin
- INSERM UMR1184 Team 'Resist', Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France
| | - Alexandra Lomont
- CHU Avicenne, Service de microbiologie clinique, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - Jean Ralph Zahar
- CHU Avicenne, Service de microbiologie clinique, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - Audrey Merens
- Hôpital d'Instruction des Armées Begin, Département de Biologie Médicale, Saint Mandé, France
| | - Christophe Isnard
- Normandie Université, UNICAEN/UNIROUEN, DYNAMICURE U1311, CHU de Caen, laboratoire de microbiologie, Caen, France
| | | | - Eric Farfour
- Hôpital Foch, service de Biologie Clinique, Suresnes, France
| | - Vincent Fihman
- CHU Henri Mondor, Unité de Bactériologie-Hygiène, Département de Prévention, Diagnostic et Traitement des infections, Créteil, France
| | - Nicolas Yin
- Institut Gustave Roussy, Service de Bactériologie, Villejuif, France
| | - Olivier Barraud
- CHU Limoges, Service de Bactériologie-Virologie-Hygiène, CIC1435, INSERM 1092, Université de Limoges, UMR, Limoges, France
| | - Hervé Jacquier
- Hôpitaux Universitaires Saint-Louis Lariboisière-Fernand Widal, Service de microbiologie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne-Gaëlle Ranc
- Hospices Civils de Lyon, Département de Bactériologie, Institut des Agents infectieux, Lyon, France
| | - Frédéric Laurent
- Hospices Civils de Lyon, Département de Bactériologie, Institut des Agents infectieux, Lyon, France
| | - Stéphane Corvec
- CHU de Nantes, Service de Bactériologie et des Contrôles Microbiologiques, Université de Nantes, Inserm, INCIT U1302, Nantes, France
| | - Louise Ruffier d'Epenoux
- CHU de Nantes, Service de Bactériologie et des Contrôles Microbiologiques, Université de Nantes, Inserm, INCIT U1302, Nantes, France
| | - Emmanuelle Bille
- CHU Necker-Enfants Malades, Laboratoire de Microbiologie, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Nicolas Degand
- CHU Nice, Laboratoire de Bactériologie, Hôpital L'archet 2, Nice, France
| | - Chloé Plouzeau
- CHU de Poitiers, service de Bactériologie et d'Hygiène hospitalière, Unité de microbiologie moléculaire et séquençage, Poitiers, France
| | - Thomas Guillard
- CHU Reims, Hôpital Robert Debré, laboratoire de Bactériologie-Virologie-Hygiène Hospitalière-Parasitologie-Mycologie, Université de Reims-Champagne-Ardenne, Inserm UMR-S 1250 P3Cell, SFR CAP-Santé; Reims, France
| | - Vincent Cattoir
- CHU de Rennes, Service de Bactériologie-Hygiène Hospitalière, Rennes, France
| | - Asaf Mizrahi
- Groupe Hospitalier Paris Saint-Joseph, service de Microbiologie Clinique, Paris, France; Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France
| | - Antoine Grillon
- CHU de Strasbourg, Plateau Technique de Microbiologie, Laboratoire de Bactériologie, Université de Strasbourg, EA7290, Strasbourg, France
| | - Frédéric Janvier
- Hôpital d'Instruction des Armées Sainte-Anne, Service de microbiologie et hygiène hospitalière, Toulon, France
| | - Cécile Le Brun
- CHRU de Tours, Hôpital Bretonneau, Service de Bactériologie-Virologie-Hygiène, Tours, France
| | - Marlène Amara
- CH Versailles-Site André Mignot, Service de Biologie, Unité de microbiologie, Le Chesnay, France
| | - Mathilda Bastide
- CH Versailles-Site André Mignot, Service de Biologie, Unité de microbiologie, Le Chesnay, France
| | - Alban Lemonnier
- Groupe Hospitalier Paris Saint-Joseph, service de Microbiologie Clinique, Paris, France
| | - Laurent Dortet
- INSERM UMR1184 Team 'Resist', Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; Centre National de Référence Associé de la Résistance aux Antibiotiques, Le Kremlin-Bicêtre, France; CHU de Bicêtre, Service de Bactériologie-Hygiène, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
| | | |
Collapse
|
6
|
Zhao Y, Chen D, Ji B, Zhang X, Anbo M, Jelsbak L. Whole-genome sequencing reveals high-risk clones of Pseudomonas aeruginosa in Guangdong, China. Front Microbiol 2023; 14:1117017. [PMID: 37125174 PMCID: PMC10140354 DOI: 10.3389/fmicb.2023.1117017] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 03/27/2023] [Indexed: 05/02/2023] Open
Abstract
The ever-increasing prevalence of infections produced by multidrug-resistant or extensively drug-resistant Pseudomonas aeruginosa is commonly linked to a limited number of aptly-named epidemical 'high-risk clones' that are widespread among and within hospitals worldwide. The emergence of new potential high-risk clone strains in hospitals highlights the need to better and further understand the underlying genetic mechanisms for their emergence and success. P. aeruginosa related high-risk clones have been sporadically found in China, their genome sequences have rarely been described. Therefore, the large-scale sequencing of multidrug-resistance high-risk clone strains will help us to understand the emergence and transmission of antibiotic resistances in P. aeruginosa high-risk clones. In this study, 212 P. aeruginosa strains were isolated from 2 tertiary hospitals within 3 years (2018-2020) in Guangdong Province, China. Whole-genome sequencing, multi-locus sequence typing (MLST) and antimicrobial susceptibility testing were applied to analyze the genomic epidemiology of P. aeruginosa in this region. We found that up to 130 (61.32%) of the isolates were shown to be multidrug resistant, and 196 (92.45%) isolates were Carbapenem-Resistant Pseudomonas aeruginosa. MLST analysis demonstrated high diversity of sequence types, and 18 reported international high-risk clones were identified. Furthermore, we discovered the co-presence of exoU and exoS genes in 5 collected strains. This study enhances insight into the regional research of molecular epidemiology and antimicrobial resistance of P. aeruginosa in China. The high diversity of clone types and regional genome characteristics can serve as a theoretical reference for public health policies and help guide measures for the prevention and control of P. aeruginosa resistance.
Collapse
Affiliation(s)
- Yonggang Zhao
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Dingqiang Chen
- Department of Laboratory Medicine, Microbiome Medicine Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Boyang Ji
- Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
| | | | - Mikkel Anbo
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Lars Jelsbak
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
- *Correspondence: Lars Jelsbak,
| |
Collapse
|
7
|
Rima M, Oueslati S, Dabos L, Daaboul D, Mallat H, Bou Raad E, Achkar M, Mawlawi O, Bernabeu S, Bonnin RA, Girlich D, Osman M, Hamze M, Naas T. Prevalence and Molecular Mechanisms of Carbapenem Resistance among Gram-Negative Bacilli in Three Hospitals of Northern Lebanon. Antibiotics (Basel) 2022; 11:antibiotics11101295. [PMID: 36289953 PMCID: PMC9598570 DOI: 10.3390/antibiotics11101295] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 09/19/2022] [Accepted: 09/19/2022] [Indexed: 12/05/2022] Open
Abstract
Carbapenem resistance (CR) is an emerging health issue. Epidemiological surveys on carbapenem-resistant Gram-negative bacilli (CR-GNB) in Lebanon remain scarce. In this study, we determined the prevalence of CR-GNB isolated between 2015 to 2019 in three hospitals in northern Lebanon: 311 CR-Enterobacterales (out of 11210; 2.8%), 155 CR-Pseudomonas (out of 1034; 15%) and 106 CR- Acinetobacter (out of 184; 57.6%) were identified. CR mechanisms were determined for 146 randomly chosen isolates: the Carba NP test revealed an enzymatic resistance to carbapenems in 109 isolates (out of 146, 74.7%). Produced carbapenemases were evaluated by the NG-Test Carba5, NG-Test OXA-23 immunochromatographic assays and PCR. Carbapenemase-producing (CP) Enterobacterales expressed blaOXA-48-like, blaNDM-like and blaVIM-like genes and CP-Pseudomonas expressed blaIMP-like and blaVIM-like genes, whereas CP-Acinetobacter expressed blaOXA-23-like genes. The NG-Test Carba5 results were confirmed by PCR sequencing and revealed several variants, such as NDM-19, VIM-62 and OXA-162, never described so far in Lebanon. Isolates with discordant results were sequenced by WGS and highlighted novel variants of the natural oxacillinases of Pseudomonas aeruginosa: blaOXA-50-like genes. Their role in carbapenem resistance should be further studied. Overall, our findings highlight an alarming situation and encourage health care centers to establish performant registration systems that could help in limiting resistance spread.
Collapse
Affiliation(s)
- Mariam Rima
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- Laboratoire Microbiologie Santé et Environnement (LMSE), Doctoral School of Sciences and Technology, Faculty of Public Health, Lebanese University, Tripoli 1300, Lebanon
| | - Saoussen Oueslati
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- Bacteriology-Hygiene Unit, Bicêtre Hospital, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Laura Dabos
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
| | - Dina Daaboul
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- Laboratoire Microbiologie Santé et Environnement (LMSE), Doctoral School of Sciences and Technology, Faculty of Public Health, Lebanese University, Tripoli 1300, Lebanon
| | - Hassan Mallat
- Laboratoire Microbiologie Santé et Environnement (LMSE), Doctoral School of Sciences and Technology, Faculty of Public Health, Lebanese University, Tripoli 1300, Lebanon
| | - Elie Bou Raad
- Clinical Laboratory, El Youssef Hospital Center, Halba 1302, Lebanon
| | - Marcel Achkar
- Clinical Laboratory, Nini Hospital, Tripoli 1300, Lebanon
| | - Osman Mawlawi
- Clinical Laboratory, Tripoli Governmental Hospital, Tripoli 1300, Lebanon
| | - Sandrine Bernabeu
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- Bacteriology-Hygiene Unit, Bicêtre Hospital, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Rémy A. Bonnin
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales, 94270 Le Kremlin-Bicêtre, France
| | - Delphine Girlich
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
| | - Marwan Osman
- Cornell Atkinson Center for Sustainability, Cornell University, Ithaca, NY 14853, USA
- Department of Public and Ecosystem Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
| | - Monzer Hamze
- Laboratoire Microbiologie Santé et Environnement (LMSE), Doctoral School of Sciences and Technology, Faculty of Public Health, Lebanese University, Tripoli 1300, Lebanon
| | - Thierry Naas
- Team ReSIST, INSERM U1184, School of Medicine, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France
- Bacteriology-Hygiene Unit, Bicêtre Hospital, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
- French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales, 94270 Le Kremlin-Bicêtre, France
- Correspondence: ; Tel.: +33-1-4521-2019
| |
Collapse
|
8
|
Volland H, Ballesté-Delpierre C, Szabó D, Gonzalez C, Takissian J, Aszalos AZ, Ostorhazi E, Farkas S, Kamotsay K, Rosenmoller M, Stankov-Pugès M, Francius L, Boutigny L, Sivan V, Simon S, Gelhaye S, Bosch J, Vila J, Naas T. Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool. J Antimicrob Chemother 2022; 77:2867-2875. [PMID: 35978470 DOI: 10.1093/jac/dkac264] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 07/15/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Lateral flow immunoassays (LFIA) have shown their usefulness for detecting CTX-M- and carbapenemase-producing Enterobacterales (CPEs) in bacterial cultures. Here, we have developed and validated the BL-DetecTool to detect CTX-M enzymes and carbapenemases directly from clinical samples. METHODS The BL-DetecTool is an LFIA that integrates an easy sample preparation device named SPID (Sampling, Processing, Incubation and Detection). It was evaluated in three University hospitals on urine, blood culture (BC) and rectal swab (RS) specimens either of clinical origin or on spiked samples. RS evaluation was done directly and after a 24 h enrichment step. RESULTS The CTX-M BL-DetecTool was tested on 485 samples (154 BC, 150 urines, and 181 RS) and revealed a sensitivity and specificity of 97.04% (95% CI 92.59%-99.19%) and 99.43% (95% CI 97.95%-99.93%), respectively. Similarly, the Carba5 BL-DetecTool was tested on 382 samples (145 BC, 116 urines, and 121 RS) and revealed a sensitivity and specificity of 95.3% (95% CI 89.43%-98.47%) and 100% (95% CI 98.67%-100%), respectively. While with the Carba5 BL-DetecTool five false negatives were observed, mostly in RS samples, with the CTX-M BL-DetecTool, in addition to four false-negatives, two false-positives were also observed. Direct testing of RS samples revealed a sensitivity of 78% and 86% for CTX-M and carbapenemase detection, respectively. CONCLUSIONS BL-DetecTool showed excellent biological performance, was easy-to-use, rapid, and could be implemented in any microbiology laboratory around the world, without additional equipment, no need for electricity, nor trained personnel. It offers an attractive alternative to costly molecular methods.
Collapse
Affiliation(s)
- Hervé Volland
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Clara Ballesté-Delpierre
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain
| | - Dóra Szabó
- Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary
| | - Camille Gonzalez
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France
| | - Julie Takissian
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France
| | - Albert Zoltan Aszalos
- Semmelweis University, Health Services Management Training Centre, Budapest, Hungary
| | - Eszter Ostorhazi
- Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary
| | - Szilvia Farkas
- Semmelweis University, Health Services Management Training Centre, Budapest, Hungary
| | - Katalin Kamotsay
- Central Microbiology Laboratory, Central Hospital of Southern Pest National Institute of Hematology and Infectious Disease, Budapest, Hungary
| | | | | | | | | | - Virginie Sivan
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Stéphanie Simon
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Stéphanie Gelhaye
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 91191 Gif-sur-Yvette, France
| | - Jordi Bosch
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain.,University of Barcelona, Hospital Clínic, Department of Clinical Microbiology - CDB, Barcelona, Spain
| | - Jordi Vila
- University of Barcelona, Institute for Global Health (ISGlobal), Hospital Clínic - Barcelona, Spain.,University of Barcelona, Hospital Clínic, Department of Clinical Microbiology - CDB, Barcelona, Spain.,CIBER de Enfermedades Infecciosas (CIBERINFEC), ISCIII, Madrid, Spain
| | - Thierry Naas
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Bacteriology-Hygiene unit, Le Kremlin-Bicêtre, France.,Team 'Resist' UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB)', INSERM, University Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.,Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-producing Enterobacterales, Le Kremlin-Bicêtre, France
| |
Collapse
|
9
|
OUP accepted manuscript. J Antimicrob Chemother 2022; 77:1785-1787. [DOI: 10.1093/jac/dkac090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Olaniran OB, Adeleke OE, Donia A, Shahid R, Bokhari H. Incidence and Molecular Characterization of Carbapenemase Genes in Association with Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa from Tertiary Healthcare Facilities in Southwest Nigeria. Curr Microbiol 2021; 79:27. [PMID: 34905085 DOI: 10.1007/s00284-021-02706-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 11/03/2021] [Indexed: 11/25/2022]
Abstract
Pseudomonas aeruginosa, resistant to multiple antibacterial agents including carbapenems, is of great global public health concern. There is limited data available regarding incidence of Metallo-Beta Lactamase producing P. aeruginosa, their molecular basis of resistance in particular carbapenem resistance and any genetic relatedness among circulating clinical isolates in Southwest Nigeria. Four hundred and thirty P. aeruginosa isolates were collected from seven tertiary care hospitals (predominantly from wound, ear, and urinary tract infections) and verified by PCR targeting oprI and oprL. Antibiotic susceptibility using 16 selected antibiotics and MBL screening was performed. The integrons (class 1, 2 and 3) and carbapenemase genes- blaGES, blaNMC-A, blaBIC-1, blaSME, blaIMP, blaVIM, blaSPM, blaNDM, blaAIM, blaDIM, blaSIM, blaGIM, blaOXA-48, blaOXA-58 were detected by PCR and were sequenced. Quantitative real-time polymerase chain reaction was used to quantify expression levels of eight efflux pump genes, ampC cephalosporinase and outer membrane porin, oprD. The isolates were genotyped using Enterobacterial Repetitive Intergenic Consensus sequence Polymerase Chain Reaction (ERIC-PCR). Four hundred and thirty P. aeruginosa isolates were subjected to antibiotic susceptibility testing, revealing that 109 (25.4%) isolates were multidrug-resistant, 47 (10.9%) were extensively drug-resistant and 25 (5.8%) were pandrug-resistant. MBL was seen in 17.0% (73/430) isolates. MBL-encoding genes; blaVIM-5 and blaNDM-1 were detected in 86.3% (63/73) isolates, with blaVIM-5 and blaNDM-1 in 35.6% (26/73) and 38.4% (28/73), respectively, whereas co-occurrence of blaVIM-5 and blaNDM-1 was found in 12.3% (9/73). Forty-one (56.2%) carbapenem-resistant P. aeruginosa strains carried class 1 integrons, while co-occurrence of class 1 and 2 integrons was seen in 12.3%. qPCR results indicated that MexXY-OprM was highly expressed pump in 58.9%, ampC upregulated in 26.0%, while oprD porin was downregulated in 65.8% isolates. ERIC-PCR results suggest that carbapenem-resistant strains exhibit genetic heterogeneity. The high incidence of MBL-encoding genes and integrons in diversified clinical P. aeruginosa from southwestern Nigeria is of great concern. The co-occurrence of blaVIM-5 and blaNDM-1 as well as resistance in general manifesting a gradient based on genotypic variation suggests that there is a strong need for efficient surveillance programs and antibiotic stewardship.
Collapse
Affiliation(s)
- Oluwatoyin B Olaniran
- Department of Pharmaceutical Microbiology, Olabisi Onabanjo University, Ago-Iwoye, Nigeria
| | - Olufemi E Adeleke
- Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Nigeria
| | - Ahmed Donia
- Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan
| | - Ramla Shahid
- Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan
| | - Habib Bokhari
- Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
- Kohsar University Murree, Murree, Pakistan.
| |
Collapse
|
11
|
Zhu Z, Yang H, Yin Z, Jing Y, Zhao Y, Fu H, Du H, Zhou D. Diversification and prevalence of the quinolone resistance crpP genes and the crpP-carrying Tn 6786-related integrative and conjugative elements in Pseudomonas aeruginosa. Virulence 2021; 12:2162-2170. [PMID: 34402737 PMCID: PMC8381794 DOI: 10.1080/21505594.2021.1962160] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The quinolone resistance crpP genes can mediate decreased susceptibility to quinolones. However, diversification and prevalence of crpP genes and crpP-carrying integrative and conjugative elements (ICEs) still need to be elucidated. In this study, genome sequencing was conducted for 200 Chinese Pseudomonas aeruginosa isolates, 16 of which were fully sequenced. All the 37 available CrpP variants were collected for phylogenetic analysis, 10 CrpP enzymes were chosen to conduct cloning and antimicrobial susceptibility test, and 22 crpP-carrying Tn6786-related ICEs were selected for detail genetic dissection analysis. Then, typing/nomenclature schemes for crpP variants and crpP-carrying ICEs were established for the first time. The 10 representative CrpP enzymes were confirmed to mediate decreased susceptibility to one to three quinolones. Tn6786-related ICEs displayed high-level diversification in both nucleotide sequences and modular structures. Mainly, massive gene acquisition/loss occurred across the whole genomes of Tn6786-related ICEs. 53.5% (107/200) of the tested clinical P. aeruginosa isolates from China carried crpP genes, which were exclusively located within chromosome-borne Tn6786-related ICEs. The crpP-carrying ICEs were at active stages of evolution and had the high potential to be an important vector for the dissemination of resistance genes besides crpP. The present study furthered the understanding of the bioinformatics and epidemiology of crpP genes and crpP-carrying ICEs.
Collapse
Affiliation(s)
- Zhichen Zhu
- Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Huiying Yang
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Zhe Yin
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Ying Jing
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Yuee Zhao
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Hongyu Fu
- Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Hong Du
- Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Dongsheng Zhou
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| |
Collapse
|
12
|
Kullappan M, Mallavarapu Ambrose J, Surapaneni KM. Understanding the binding conformation of ceftolozane/tazobactam with Metallo-β-lactamases VIM-5 and IMP-7 of Pseudomonas aeruginosa: A molecular docking and virtual screening process. J Mol Recognit 2021; 34:e2898. [PMID: 33780080 DOI: 10.1002/jmr.2898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2020] [Revised: 03/03/2021] [Accepted: 03/04/2021] [Indexed: 11/11/2022]
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is one of the community-acquired and healthcare-associated infections causing organisms. It has become resistant to most of the available antibiotics and is termed multi-drug resistance (MDR). There are a limited number of antibiotics are available to treat such MDR organism causing infections. The ceftolozane/tazobactam is one among the combination drug therapy (CDT) prescribed for the treatment of MDR causing infections. The resistance for the same CDT was observed in the MDR P. aeruginosa harboring VIM-5 and IMP-7 Metallo beta (β)-lactamases (MBLs). To explore the resistance mechanism at the molecular level, docking studies were carried out for antibiotics against VIM-5 and IMP-7 MBLs. The Zn2 metal ions carry out the nucleophile attack on the carbonyl carbon of the β-lactam ring along with conserved water molecules. To find lead compounds against the MBLs, a virtual screening process was carried out. We have employed MODELLER for structure modeling, AutoDock for molecular docking and AutoDock Vina, Molinspiration, PASS prediction & admetSAR in virtual screening. The search of low binding energy ceftolozane analogs against VIM-5 and IMP-7 MBLs has resulted in the ZINC000029060075 and ZINC000009163636 analogs. Similarly, the screening of high binding energy inhibitors against VIM-5 and IMP-7 MBLs has resulted in ZINC000003831503 and ZINC000000897247 tazobactam analogs respectively. The ADMET prediction results in the non-toxicity of the lead compounds. Our study may provide new insights for the scientist who are designing novel drugs against MDR P. aeruginosa causing infections.
Collapse
Affiliation(s)
- Malathi Kullappan
- Department of Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai, Tamil Nadu, India
| | - Jenifer Mallavarapu Ambrose
- Department of Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai, Tamil Nadu, India
| | - Krishna Mohan Surapaneni
- Departments of Biochemistry, Clinical Skills & Simulation and Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai, Tamil Nadu, India
| |
Collapse
|